JP2008508253A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008508253A5 JP2008508253A5 JP2007523167A JP2007523167A JP2008508253A5 JP 2008508253 A5 JP2008508253 A5 JP 2008508253A5 JP 2007523167 A JP2007523167 A JP 2007523167A JP 2007523167 A JP2007523167 A JP 2007523167A JP 2008508253 A5 JP2008508253 A5 JP 2008508253A5
- Authority
- JP
- Japan
- Prior art keywords
- ccr2
- therapeutic
- administering
- therapeutic agent
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59268304P | 2004-07-30 | 2004-07-30 | |
| PCT/IB2005/002162 WO2006013427A2 (en) | 2004-07-30 | 2005-07-18 | Treatment of ccr2 mediated diseases or disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008508253A JP2008508253A (ja) | 2008-03-21 |
| JP2008508253A5 true JP2008508253A5 (enExample) | 2008-08-14 |
Family
ID=35207829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007523167A Withdrawn JP2008508253A (ja) | 2004-07-30 | 2005-07-18 | Ｃｃｒ２を介した疾患又は障害の治療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20090196823A1 (enExample) |
| EP (1) | EP1778285A2 (enExample) |
| JP (1) | JP2008508253A (enExample) |
| KR (1) | KR20080044360A (enExample) |
| CN (1) | CN101005855A (enExample) |
| AU (1) | AU2005268545A1 (enExample) |
| BR (1) | BRPI0513953A (enExample) |
| CA (1) | CA2575612A1 (enExample) |
| IL (1) | IL180675A0 (enExample) |
| MX (1) | MX2007001204A (enExample) |
| NO (1) | NO20070996L (enExample) |
| RU (1) | RU2007103332A (enExample) |
| WO (1) | WO2006013427A2 (enExample) |
| ZA (1) | ZA200700823B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7629351B2 (en) | 2006-07-28 | 2009-12-08 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process |
| US7671062B2 (en) | 2006-07-28 | 2010-03-02 | Bristol-Myers Squibb Company | Modulators of chemokine receptor activity, crystalline forms and process |
| US7687508B2 (en) | 2006-07-28 | 2010-03-30 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| PE20110774A1 (es) | 2008-08-18 | 2011-10-13 | Amgen Fremont Inc | Anticuerpos para ccr2 |
| US8383812B2 (en) | 2009-10-13 | 2013-02-26 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
| US9726666B2 (en) | 2011-06-13 | 2017-08-08 | Tla Targeted Immunotherapies Ab | Diagnosing and treating inflammatory diseases |
| DK2723360T3 (en) * | 2011-06-27 | 2017-08-28 | Univ Pierre Et Marie Curie Paris 6 | CCR2 antagonist peptides |
| WO2022235440A1 (en) * | 2021-04-21 | 2022-11-10 | The United States Government As Represented By The Department Of Veterans Affairs | Method for treating traumatic brain injury, spinal cord injury, or stroke using small molecule inhibitors of ccr2 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6312689B1 (en) * | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
| FR2792837B1 (fr) * | 1999-04-29 | 2001-07-13 | Centre Nat Rech Scient | Medicaments utiles pour le traitement des troubles de la regulation de la masse adipeuse et des maladies associees aux troubles de la production de leptine |
| US20050245537A1 (en) * | 2002-04-24 | 2005-11-03 | Noboru Tsuchimori | Use of compounds having ccr antagonism |
| JP2007523871A (ja) * | 2003-07-15 | 2007-08-23 | メルク エンド カムパニー インコーポレーテッド | ケモカイン受容体活性の７および８員複素環式シクロペンチルベンジルアミドモジュレーター |
| MXPA06007000A (es) * | 2003-12-18 | 2006-08-31 | Incyte Corp | Derivados de 3-cicloalquilaminopirrolidina como moduladores de receptores de quimiocina. |
-
2005
- 2005-07-18 CA CA002575612A patent/CA2575612A1/en not_active Abandoned
- 2005-07-18 BR BRPI0513953-8A patent/BRPI0513953A/pt not_active IP Right Cessation
- 2005-07-18 MX MX2007001204A patent/MX2007001204A/es unknown
- 2005-07-18 WO PCT/IB2005/002162 patent/WO2006013427A2/en not_active Ceased
- 2005-07-18 KR KR1020087010937A patent/KR20080044360A/ko not_active Ceased
- 2005-07-18 EP EP05777347A patent/EP1778285A2/en not_active Withdrawn
- 2005-07-18 RU RU2007103332/14A patent/RU2007103332A/ru not_active Application Discontinuation
- 2005-07-18 AU AU2005268545A patent/AU2005268545A1/en not_active Abandoned
- 2005-07-18 CN CNA2005800276608A patent/CN101005855A/zh active Pending
- 2005-07-18 JP JP2007523167A patent/JP2008508253A/ja not_active Withdrawn
- 2005-09-16 US US11/658,989 patent/US20090196823A1/en not_active Abandoned
-
2007
- 2007-01-11 IL IL180675A patent/IL180675A0/en unknown
- 2007-01-29 ZA ZA200700823A patent/ZA200700823B/xx unknown
- 2007-02-21 NO NO20070996A patent/NO20070996L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008501776A5 (enExample) | ||
| EA200801071A1 (ru) | Способы и композиции для применения в целях лечения пациентов с положительным по аутоантителам заболеванием | |
| NZ595262A (en) | Use of il-23 and il-27 antagonists to treat autoimmune ocular inflammatory disease | |
| DE602005018763D1 (de) | Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität | |
| WO2007128761A3 (de) | Verwendungen von dpp iv inhibitoren | |
| EA033415B1 (ru) | Способы лечения ожирения, применение ингибитора dpp-4 в этих способах и способ лечения пациентов, страдающих диабетом типа 2 | |
| RU2012124268A (ru) | Бензимидазольные соединения и их применения | |
| EA200700214A1 (ru) | Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией | |
| WO2004039325A3 (en) | Treatment of pain with jnk inhibitors | |
| JP2004517824A5 (enExample) | ||
| JP2008508253A5 (enExample) | ||
| RU2008116567A (ru) | Биомаркеры | |
| UA99094C2 (ru) | Способ лечения пациента с системной красной волчанкой | |
| Ren et al. | Effect of intermittent pneumatic compression with different inflation pressures on the distal microvascular responses of the foot in people with type 2 diabetes mellitus | |
| RU2007103332A (ru) | Способы лечения опосредуемых ccr2 заболеваний или нарушений | |
| NO20055531L (no) | Preparat for forbedret kognisjon og hukommelse | |
| RU2013112890A (ru) | Терапевтическое применение 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина | |
| BRPI0409699A (pt) | métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos | |
| WO2008057363A3 (en) | Use of vitamin d derivatives to enhance delivery of therapeutics and oxygen to tumors | |
| Dobrosielski et al. | Associations between vasodilatory capacity, physical activity and sleep among younger and older adults | |
| ATE487480T1 (de) | Perhexilin zur behandlung von chronischer herzinsuffizienz | |
| ATE446309T1 (de) | Den kapillarwiderstand verbessernde peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu deren anwendung | |
| WO2007041268A3 (en) | Transporter-targeted methods of diagnosis and treatment | |
| JP2004532389A5 (enExample) | ||
| Komatsuzaki et al. | Suppression of osteopontin functions by levocetirizine, a histamine H1 receptor antagonist, in vitro |